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ABSTRACT
p53 is an important gene, involved in apoptosis (programmed cell death), DNA repair, and cell cycle progression.
We explore the selective advantages and disadvantages of mutations in the p53 gene on tumor cells, and the
heterogeneity of tumor cell populations. Based on an evolutionary computational approach, our model considers
changes in mutation rate caused by lack of DNA repair processes, and the lack of apoptosis caused by mutations in
p53. We find that the degree of robustness of p53 to mutations has a significant effect on the tumor heterogeneity
and “fitness”, with clinical consequences for people who inherit p53 mutations.
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1. INTRODUCTION
One in three people are affected by cancer in their lifetime.1 Cancer is caused by multiple DNA mutations that
allow cells to proliferate without limit.2 The p53 protein is a potent tumor suppressor, and plays a major role
in maintaining a healthy cell cycle. During the cell cycle, however, DNA inside cells experiences spontaneous or
environmentally induced mutations. Mutations occurring in vital parts of the DNA sequence can be deleterious
for the cell.
One type of mutation that can alter DNA sequences is base pair substitution mutations.3 As the name
suggests, base pair substitution mutations occur when one of the nucleotide bases is changed; this change is
classified as either a transition or a transversion. A transition occurs when a purine (A or G) is changed to a
purine or a pyrimidine (C or T, or U in RNA) to a pyrimidine. For example, consider a base pairing of guanine
(a purine) and cytosine (a pyrimidine). If during translation the guanine becomes adenine (another purine),
the result is the base pairing of adenine and cytosine in the new strand of DNA. If instead, the guanine had
been changed to cytosine or thymine (or uracil in RNA), the result would be a base pairing of two pyrimidine’s,
which is genomically unstable. This type of mutation, when a purine is changed to a pyrimidine or a pyrimidine
to a purine, is known as a transversion.4 Because of the speed at which transcription occurs, there is a large
window of opportunity for errors to occur. Some mutations, however, can be silent (i) if the mutation results in
a change of the codon, but not the amino acid it codes for, or (ii) if it alters the amino acid, but not the protein.
Conversely missense mutations alter the genes such that the amino acid coded for is changed, or codons that
originally coded for amino acids are transformed into stop codons and vice-versa.3 Mutations to either the p53
gene itself, or the pathways activated by p53 are the single most common mutations found in cancer and have
been implicated in over 50 per cent of cancer cases.5, 6 It is a mutation of this gene or its effector pathways that
consequently results in malignant tumours.7
In healthy cells, the p53 protein is present at very low concentrations, in an inactive form. Levels of p53 in
the cell are maintained by a negative feedback loop between it and another protein Mdm2.8, 9 There are several
checkpoints in the cell cycle which can prevent the cell from progressing if DNA damage is detected. Activation
of the p53 protein can occur at two of these checkpoints in the cell cycle. If DNA damage is detected, p53 is
Send correspondence to Derek Abbott
E-mail: dabbott@eleceng.adelaide.edu.au, Telephone: +61 8 8303 5748
Biomedical Applications of Micro- and Nanoengineering II, edited by
Dan V. Nicolau, Proc. of SPIE Vol. 5651 (SPIE, Bellingham, WA, 2005)
1605-7422/05/$15 · doi: 10.1117/12.602423
144
indirectly activated and stops cells in the G1 and G2 phase from progressing, slows down cells in the S phase
and induces transcription of repair genes.10 Such forms of DNA damage that have been shown to activate p53
include those caused by ultraviolet (UV) light, other ionizing radiation, and exposure to radio-mimetic drugs.11
Activation of p53 in response to DNA damage increases the ability of the p53 protein to bind to DNA11 and
causes a decrease in its affinity for Mdm2 and hence a decrease in degradation of itself.12 Simultaneously, the
p53 protein induces apoptosis and initiates transcription of proteins involved in DNA repair and cell cycle arrest.6
Cell cycle arrest restricts the cell from entering into the next phase in the cell cycle, until the DNA damage has
been repaired.12 If the DNA damage is too severe, then the cell will undergo programmed cell death, known as
apoptosis. This can be mediated either, by p53 initiating transcription of proteins such as the Bax protein; or
directly, by stimulation of the mitochondria to produce excess toxic reactive oxygen species.8
Table 1 identifies some of the mutations that can occur and their affects on the activities of p53.
Table 1. From Vogelstein et al.,8 this table shows the effect of mutations on p53 and the many ways it may malfunction
in tumors.
Mechanism of inactivating
p53
Typical tumors Effect of inactivation
Amino-acid-changing mutation
in the DNA-binding domain
Colon, breast, lung, bladder,
brain, pancreas, stomach,
esophagus and many others
Prevents p53 from binding to
specific DNA sequences and ac-
tivating the adjacent genes
Deletion of the carboxy-
terminal domain
Occasional tumors at many dif-
ferent sites
Prevents the formation of
tetramers of p53
Multiplication of the Mdm2
gene in the genome
Sarcomas, brain Extra Mdm2 stimulates the
degradation of p53
Viral infection Cervix, liver, lymphomas Products of viral oncogenes bind
to and inactivate p53 in the cell,
in some cases stimulating p53
degradation
Deletion of the p14ARF gene Breast, brain, lung and others,
especially when p53 itself is not
mutated
Failure to inhibit Mdm2 and
keep p53 degradation under con-
trol
Mislocalization of p53 to the cy-
toplasm, outside the nucleus
Breast, neuroblastomas Lack of p53 function (p53 func-
tions only in the nucleus)
DNA is the only macromolecule in the body that is repaired by cells.3 Eukaryotic repair mechanisms play
a major role in maintaining the integrity of the genome.4 In cells, DNA repair is constantly occurring and
is essential for their survival. DNA damage reversal is the simplest form of repair; enzymatic action by DNA
ligase repairs simple breaks in one strand of the DNA.3 Another form of DNA repair is damage removal, of
which there are three distinct forms; base excision repair (BER), nucleotide excision repair (NER) and mismatch
repair (MMR).13 Although not truly a repair mechanism, cells can also develop ways of coping with the damage
(damage tolerance).3
Evidence, from both mouse and human models, has shown direct or indirect involvement of p53 in nucleotide
excision repair.14, 15 Lesions that distort the double helix, such as a T-dimer, are repaired by NER.4 NER
involves the excision of an oligonucleotide; this comprises the breaking of phosphodiester bonds, on the same
strand, on either side of the lesion; the subsequent gap is filled DNA ligase and repair synthesis.16
When p53 function is reduced due to mutations, the DNA repair capabilities of the cell are reduced.2 The
cell is unable to cease cell cycle progression at DNA checkpoints and perform DNA repair, so the cell will
continue through the cell cycle and the daughter cells will receive mutated DNA, or incomplete or broken sets
of chromosomes.12 Ordinarily, DNA damage, or telomere malfunction would trigger apoptosis through p53 to
remove these cells,17 however mutations to p53 or its effectors can prevent programmed cell death occurring.
The lack of apoptosis causes uncontrolled cell proliferation despite DNA damage and has been shown to promote
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oncogenic transformations and tumor development in mouse model systems.2, 17 Attardi and Jacks performed
studies on both homozygous and heterozygous mice for a deletion in the p53 gene.18 Their results showed that
both groups of mice developed tumors at a high frequency; however the homozygotes had a significantly shorter
average latency for the tumors and shorter life span. Their studies of differences between the two sets of mice
also indicated that the affects of p53 inhibition vary in different tissue types.
The revelation that checkpoint function has been strongly implicated in the prevention of cancer,10 has
provided significant breakthroughs in research to developing alternative cancer treatments. Such treatments
include the reintroduction of wild type p53 to p53 mutant tumor lines, which has been shown to induce apoptosis
and tumor regression, when performed in conjunction with chemotherapy.17 Other suggested therapeutic
strategies involving p53 include the restoration of p53 function to mutant p53 tumors by p53 gene therapy; also,
drugs that are able to mimic the effects of p53 or modify its effector pathways may useful.7 The p53 has also
been suggested as a diagnostic tool for physicians. Polymerase chain reaction (PCR)-based techniques have been
used to detect mutant p53 in exfoliated cells in bladder and lung cancers.7 This would be a useful strategy in
early detection of cancers, or identifying potential cancer patients.
Here we look at the effects of mutation and repair rates and apoptosis on a population of cells through a
number of generations. We propose a model that represents a population of cells of given genome length, initially
set with a random number of mutations, that reproduce by asexual recombination. The behavior of p53 is modeled
by considering part of the genome to be a p53 gene, with two separate regions: one governing apoptosis, the
other governing repair of mutations. We consider different mutation rates, repair rates, the number of mutations
before apoptosis occurs, and the number of mutations before each region of p53 is significantly affected. The
results on the growth and heterogeneity of tumor populations are determined, with implications for both when
p53 mutations should be detected, and for treatment of p53.
2. METHODS
A binary string of given length, G, was used to represent each individual; each bit could be interpreted as being
an allele or a base pair etc. A “0” was defined as being a healthy bit/allelle and a “1” a mutated bit/allelle. The
phenotype of each genome was expressed as the number of mutations it contained (ie. the sum of “1” bits):
Ix = displaystyle
G∑
i=1
xi, (1)
where xi is the ith bit of the string.
The fitness function for each individual was simply the sum of “0” bits and could be expressed in terms of Ix,
as:
F (x) = G − Ix. (2)
The initial progeny was randomly created as an N by G array, where each row of the array represented an
individual, giving an initial population size N . Each bit of the array was set with a 90 percent probability of
being healthy and 10 percent probability of being mutated.
A portion, g, of each genome was used to represent the p53 gene. The size of g was set with respect to G.
As discussed previously, the p53 gene has numerous roles in maintaining a healthy cell cycle, such as cell cycle
arrest, apoptosis and DNA repair.8 In our model, the region representing the p53 gene was designed such that
60 percent coded for apoptosis, g1, and the other 40 percent for DNA repair, g2.
The evolution of the progeny was studied over fifty cell cycles/generations. During each cell cycle, all indi-
viduals underwent conditional spontaneous mutation, DNA repair and apoptosis.
Our model considers both silent and missense base pair substitution mutations. Cells were mutated with
mutation rate m. The rate of spontaneous mutations for E. coli was stated by Elliott to be 1 error in every 108
nucleotides replicated.4 Other rates of mutation have been found to be in the order of 1 nucleotide change per
109 nucleotides per cell generation for other bacteria12 and somewhere in the order of 1 in 106 or 105 nucleotides
replicated for humans.4 Since our model considers only genomes of one hundred bits and the number of
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generations it considers is limited due to the time required to perform the computations, using mutation rates of
1/106 over a limited number of generations would produce little or no effect on the population. To compensate
for this, much larger mutation rates, in the range of 0.05 to 0.50, were used.
For individuals in our model to be eligible for DNA repair, a minimum fitness was required of the g2 region.
Each individual that satisfied this minimum fitness level underwent DNA repair, with a repair rate m1. Again,
this rate had no reflection on the actual rate of repair occurring in cells. The range of values used for m1 was the
same as those used for m. Various combinations of m and m1 were used, such as m1 = m, m1 = 2m, m1 = 10m,
etc. When cells underwent DNA mutation or repair, each bit/allelle in its genome had an equal likelihood of
experiencing a mutation.
If an individual did not meet the minimum fitness requirement then apoptosis of the cell was required. For
apoptosis to occur, however, a minimum fitness of the g1 region was also essential. Individuals, which required
apoptosis (eg. F (x) < f) and that had a g1 region with minimum fitness (eg. F (g1) > p1 ), were then selected for
apoptosis. If the g1 region was too mutated, then apoptosis would not occur and the severely mutated cell would
survive and could then undergo cell division to produce two daughter cells with extremely mutated genomes.
Cell division occurred at the end of each cell cycle, so that each successive generation had twice the population
size of its parent generation. To ensure the cells did not proliferate out of control, random individuals were killed
off directly after cell division so that the population size was kept to a maximum of ten thousand.
3. RESULTS
The genome size was set to G = 100, with g = 8 and the initial population size set to N = 50. For cells to
survive, it is essential that the rate of repair exceed the rate of mutation, so initially the mutation rate was kept
constant at m = 0.05 and the following repair rates were used: m1 = 0.05; m1 = 0.1; m1 = 0.2 and m1 = 0.5.
Due to the random element within our model, ten trials were run for each of these repair rates, recording the
mean phenotype (number of mutations) of the progeny at each generation, and the average of each was used.
The mean phenotype Īx(t) was then plotted against time t (in cell cycles), for each repair rate considered,
and the resultant plot in Figure 1 shows a second order polynomic relationship between the mean phenotype
Īx(t) and time t.
From these plots, we see that the phenotype of the population continues to increase with time, for all the
repair rates. In other words, if we continued to observe the genomic activity of the cells, all the cells in the
progeny would eventually acquire a phenotype of 100 (i.e. 100 mutations); the difference between the curves,
however, is the rate of mutation acquisition. The latency to reach this level of mutation would be different for
the different repair rates.
Differentiating Īx(t) with respect to t we see the rate of mutation acquisition per cell division/generation.
Table 2 shows the mean phenotype Īx(t) and its derivative Īx(t)′ for each curve in Figure 1.
Table 2. Mean phenotype Īx(t) and its derivative Īx(t)
′ for various repair rates (mutation rate = 0.05)
Repair rate Īx(t) Īx(t)′
0.05 −0.0173t2 + 2.3359t + 12.118 (R2 = 0.997) −0.346t + 2.3359
0.1 −0.0074t2 + 1.6155t + 12.703 (R2 = 0.9962) −0.148t + 1.6155
0.2 0.0018t2 + 0.8957t + 11.206 (R2 = 0.9986) 0.0036t + 0.8957
0.5 0.0052t2 + 0.3179t + 6.187 (R2 = 0.9943) 0.0104t + 0.3179
Plotting the derivative Īx(t)′ for each mutation rate in Figure 2, we see that the curves for m1 = 0.05 and
m1 = 0.1 both have a decreasing mutation acquisition rate, but the curves for m1 = 0.2 and m1 = 0.5 both have
an increasing rate of mutation acquisition.
From these results, we hypothesize that the rate of mutation acquisition is of the form: ax2 + bx + c (and
concave ∴ a < 0). Integrating this back with respect to t, to give the expression for the mean phenotype,
would infer that the curves representing the behavior of the phenotype over time, are in fact of the form:
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Figure 1. Mean phenotype (number of mutations) of cells against generations. Mutation rate m = 0.05. Repair rates
considered: m = 0.05 m = 0.1 m = 0.2 and m = 0.5. The actual curves are represented by the four different line types.
A cubic polynomial was fitted to each of the curves and these are shown in bold. The equations for each of the ”fitted”
polynomials appears to the right of the respective curve, along with its ”goodness of fit”.
ax3 + bx2 + cx + d, rather than ax2 + bx + c. The rate of mutation acquisition is at first slow and increasing, up
to a threshold point; after this point, the cell continues to gain mutations, but the rate of acquisition decreases.
If this theory is in fact correct, then it would follow that the first two curves, are in fact passed the threshold
point at time t = 0. The turning point at which the mutation acquisition rate goes from increasing to decreasing
occurs at some point t < 0 and hence does not appear. Since the second two curves (m1 = 0.2 and m1 = 0.5)
still have an increasing rate of mutation acquisition, it would suggest that this “threshold”point has not yet been
reached. If we were to continue to observe the behavior of the two curves m1 = 0.2 and m1 = 0.5, then, they
would reach their “threshold point” and the rate of mutation acquisition would decrease until the entire genome
was mutated (i.e. Īx(t) = 100).
To test this theory, we considered the case m = 0.05, m1 = 0.5 and followed the evolution of the cell
population through 200 cell cycles. The resultant plot is shown in Figure 3. As can be seen from the plot, the
function for this curve is a cubic polynomial (with “goodness of fit” R2 = 0.9984), which supports our theory
that the rate of mutation would continue increasing to a point and then begin to decrease. Differentiating this
and solving for Īx(t) = 0 will give the cell cycle at which the turning point occurs.
We repeated this procedure, this time keeping the repair rate constant at m1 = 0.05 and considering mutation
rates m = 0.05, m = 0.01 and m = 0.5. The mean phenotype was then plotted against time t (in cell cycles), for
the three different mutation rates considered (Figure 4). Once again, we see large rates of mutation acquisition at
the beginning, which decrease with time. Once the entire population has a fully mutated genome, the individuals
in the population can no longer acquire mutations and consequently the mutation acquisition rate will be zero.
The curves representing the mean phenotype of the population, may be better expressed using the logistic
differential equation.19 This model is based on the assumption that a population grows at a rate proportional
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Figure 2. Rate of mutation acquisition per cell cycle. Mutation rate m = 0.05. Repair rates considered: m1 = 0.05
m1 = 0.1 m1 = 0.2 and m1 = 0.5. The equations from Figure 1, for the fitted polynomials, were differentiated with
respect to t and plotted. Each line shown, displays the mean rate of mutation acquisition at time t for the respective
repair rates considered.
to the the size of the population and is expressed as:
dĪ
dt
= kĪ(1 − Ī
K
, (3)
where: Ī is the mean phenotype/number of mutations,
k is the proportionality constant and
K is the carrying capacity.
For our model, the carrying capacity K would be 100, (the length of the the genome G) and the proportionality
constant k would be determined by the ratio between the mutation and repair rates, (m and m1 respectively).
4. DISCUSSION
From the results obtained, it was suggested that the mean phenotype Īx(t) with respect to time is determined
by a cubic polynomial of t. The rate of mutation acquisition increases to a point, before decreasing as the mean
phenotype of the progeny approaches a maximum.
In healthy cells, the acquisition of mutations is kept in check by the repair mechanisms of the cell. This is
best represented by the curve in Figure 1 where the rate of repair is ten times the rate of mutation (m1 = 0.5,
m = 0.05). There is a greater latency in obtaining mutations, when compared to all the other cases (i.e. a
significantly lower rate of mutation acquisition). Over time, however more and more mutations are acquired and
the repair mechanisms of the cell become less efficient, allowing the rate at which these mutations are acquired
to increase, up to a point. Past this point, as the cell becomes more and more mutated, it is no longer able to
sustain this increasing rate of mutation. Consequently, this rate drops off, until the entire genome is mutated.
Cells in our body behave in a similar manner. Over time, they acquire mutations, which are ordinarily kept
in check by repair mechanisms, such as those initiated by the p53 gene. As cells age, however, the efficiency
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Figure 3. The genomic activity of the case with mutation rate m = 0.05 and repair rate m1 = 0.5 was observed over
200 cell cycles. The actual curve is the fine line and the bold line over the top is the fitted polynomial. The equation for
the polynomial is shown, with its ”goodness of fit” value. Watching the evolution over a longer time period, showed that
the shape of the curve changes from convex to concave. The point of inflection is the ”threshold point” where the rate of
mutation acquisition changes from increasing to decreasing.
of the repair mechanisms decrease and the cell develops more and more mutations. As the mutations in a cell
accumulate, the cell can become malignant, and a tumor will result. We see in Figure 4, with the mutation rate
ten times the repair rate, the repair rate of the cell has virtually no impact on keeping the mutation rate in check
and the progeny of cells accumulate a mean phenotype of 100 after only 10 cell cycles.
Future research planned involves using more realistic mutation and repair rates, and the interactions of gene
and drug therapies on these, to determine their usefulness and efficacy. Another interesting question is, given
the mutations in p53, what are the benefits and drawbacks in using radiotherapy, which while killing off some
cells will further mutate others?
5. CONCLUSION
Our model offers a simplistic view of the effects of mutation on a population of cells. The model considers the
role of p53 in maintaining genomic integrity, and investigates how mutations to this gene affect the evolution of
a population of cells. We see that the repair mechanisms of the cell are not able to prevent mutations of the
cell indefinitely, but instead increase the latency of mutation acquisition. Because the efficiency of the repair
mechanism in cells decreases with age, all replicating cells are predisposed to potentially developing into a tumor
with further mutations fixed in upon replication.20 Methods that can prolong the time that mutation of the
cell is kept in check will reduce the potential of tumor development. The results show that increasing the ratio
between the repair and mutation rates increases the ability of the cell to keep mutations in check for longer. Any
future gene therapies or drug treatments could potentially alter these rates in order to prolong life or possibly
even prevent tumors progressing through to cancer.
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Figure 4. Mean phenotype (number of mutations) of cells against generations. Repair rate m = 0.05. Mutation rates
considered: m = 0.05 m = 0.1 and m = 0.5. The concave shape of the curves indicates that the rate of mutation
acquisition is decreasing, and hence the inflection points would have occurred at time t < 0. For all curves, mutations are
acquired at a decreasing rate, until a maximum phenotype of 100 is obtained.
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